An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).

This study, called PALACE3, looks at whether patients with esophageal (food pipe) cancer who respond well to a combination of chemotherapy, radiation, and immunotherapy might be able to avoid surgery while still achieving excellent cancer control. It is testing an "organ-preserving" strategy. **You may be eligible if...** - You have been diagnosed with resectable esophageal squamous cell cancer (a specific type of esophageal cancer confirmed by biopsy) - Your cancer is locally advanced but has not spread to distant organs - Your ECOG performance status is 0 or 1 (you are active and able to carry out daily activities) - You are willing to sign the consent form **You may NOT be eligible if...** - You have an active autoimmune disease or history of autoimmune disease - You need long-term steroids or other immune-suppressing medications - You have a history of symptomatic interstitial lung disease (scarring of the lungs) - You are allergic to the study drugs - You are pregnant or breastfeeding - You have previously received chemotherapy, radiation, targeted therapy, or immunotherapy for this or any other cancer Talk to your doctor to see if this trial is right for you.